Research Study on Risks related to the distribution of Covid Vaccine - GRM Institute

Research Study on Risks related to the distribution of Covid Vaccine

Distribution of Covid Vaccine

By Aditya Sai Kanaparthy and Chhavi Bhardwaj (PGDRM Batch Jan’21-22)

 

Vaccine Cold Chain Distribution Network In India

 

Raw Material Constraint In Production Scaling

 

Transport and Storage Challenges: Temperature Constraints

 

  • India has a 28,000-unit cold storage network that is used for the government’s universal immunization programme. ​
  • Since this demand is not permanent, a majority of companies are looking for coordinated efforts to ramp up short-term competencies.

 

Increased Labor Requirements

 

Complex protocols for handling and preparing COVID-19 vaccines, as well as the added precautionary observation period after patients are injected, have the potential to strain labor capacities or divert workers from other critical roles.

Since vaccines are approved and assuming the distribution capabilities are resolved, comes the question of who will administer the vaccine?

IT Challenges and Waste Management

 

Wastages at Points of Care

  • Errors in storing, preparing, or scheduling the administration of doses at points of care will have significant consequences. ​
  • Failure to ensure that recipients attend their appointments will not only prevent individual immunity, it could also lead to product wastage.​
  • Proper on-site storage conditions are also of critical importance.​
  • The current mRNA vaccines will pose a larger challenge for on-site storage because of the temperature requirements.​

IT Challenges

  • IT systems, including vaccine-tracking systems (such as CDC’s VTrckS) and immunization information systems (IIS), will be essential for allocating, distributing, recording, and monitoring the deployment of vaccines. ​
  • Ensuring that these can operate at an unprecedented scale and are configured for a two-dose vaccine schedule has become a major software development, data-hosting, and operational challenge. ​
  • additionally, it will remain vital that these systems protect patient privacy and are secure against cyber threats, given the potential for hackers and criminals to cause damage. Cyberattacks have already occurred against COVID-19-vaccine developers and regulators.​
  • The contact tracing tools of earlier in the pandemic were generally unsuccessful because they did not give residents a sense of adequate privacy considerations, i.e. location tracking. These challenges must be met as well. ​

 

Quality Assurance
  • Generating yields while ensuring the safety and efficacy of each dose poses quality-assurance challenges. ​
  • A chain of custody will need to be maintained at every step of the supply chain — to ensure a verifiable transcript of the vaccine’s lifecycle and journey​
  • To produce a new class of vaccines—such as those based on mRNA or viral vectors—at an unprecedented scale (1.8 billion to 2.3 billion doses by mid-2021), manufacturers have required massive volumes of inputs, a larger technical workforce, and a much-expanded ecosystem of production facilities Understanding and managing large inherent variability in manufacturing.​

Read the complete research here: Risks in COVID Vaccine distribution by Aditya sai and chavvi bharadwaj

Design and Developed by KodeForest @ All Rights Reserved by KodeForest

Pages